Answers are grounded in this paper and cite their sources.
Immune checkpoint blockade (ICB) can restore antitumor T-cell activity, but immune-desert, immune-excluded, and T-cell-inflamed yet dysfunctional tumors present different forms of resistance. Nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H2S) are endogenous gasotransmitters that influence vascular function, redox signaling, metabolism, and immunity; molecular hydrogen (H2) is a distinct bioactive gas under investigation. This Perspective evaluates whether gas-based interventions can address specific barriers to ICB and differs from broad surveys of gas nanomedicines by linking tumor immune phenotypes to exposure verification, causal immune readouts, delivery design, and clinical decision gates. Effects depend on concentration, site, source, and duration and may suppress immunity. NO-releasing nanocarriers and multicomponent NO-generating nanoreactors have shown vascular and immune effects in preclinical systems, whereas a ten-patient phase I intratumoral NO report provides preliminary safety and feasibility information without controlled evidence of clinical efficacy. CO and H2S strategies remain predominantly preclinical, and human H2 findings are exploratory. We distinguish biomarkers of gas exposure and target engagement from immune remodeling and patient benefit, discuss molecular imaging and microbiome-related confounding, and propose mechanism-matched combination schedules and safety requirements. Gas-based treatment should therefore be tested against predefined resistance mechanisms rather than presumed to convert all cold tumors into ICB-responsive lesions.
No takes yet. Share an insight, caveat, or question.
Clemente‐Suárez et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: